All Photos(3)



Iron(III) citrate

technical grade

Ferric citrate, Iron(III) citrate hydrate, Iron(III) citrate
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
EC Number:
MDL number:
PubChem Substance ID:


technical grade

Quality Level


16.5-18.5% Fe basis (iodometric)




Fe, 16.5-18.5%


cell culture | mammalian: suitable


battery manufacturing

SMILES string




InChI key


Looking for similar products? Visit Product Comparison Guide

Related Categories

Storage Class Code

11 - Combustible Solids



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificate of Analysis

Certificate of Origin

More documents

Quotes and Ordering

Guus A M Kortman et al.
PloS one, 7(1), e29968-e29968 (2012-01-25)
Recent trials have questioned the safety of untargeted oral iron supplementation in developing regions. Excess of luminal iron could select for enteric pathogens at the expense of beneficial commensals in the human gut microflora, thereby increasing the incidence of infectious
Keiji Nishida et al.
PLoS biology, 10(2), e1001269-e1001269 (2012-03-06)
Most organisms are simply diamagnetic, while magnetotactic bacteria and migratory animals are among organisms that exploit magnetism. Biogenic magnetization not only is of fundamental interest, but also has industrial potential. However, the key factor(s) that enable biogenic magnetization in coordination
Keitaro Yokoyama et al.
American journal of nephrology, 36(5), 478-487 (2012-11-14)
JTT-751 (ferric citrate hydrate) is a novel oral, iron-based phosphate binder being developed for the treatment of hyperphosphatemia among chronic kidney disease patients who are on dialysis. This study investigated the dose-response and safety of JTT-751 among Japanese hemodialysis patients.
Jamie P Dwyer et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 759-766 (2013-02-02)
Most dialysis patients require phosphate binders to control hyperphosphatemia. Ferric citrate has been tested in phase 2 trials as a phosphate binder. This trial was designed as a dose-response and efficacy trial. Prospective, phase 3, multicenter, open-label, randomized clinical trial.
Petra Vukosav et al.
Analytica chimica acta, 745, 85-91 (2012-09-04)
A detailed study of iron (III)-citrate speciation in aqueous solution (θ=25°C, I(c)=0.7 mol L(-1)) was carried out by voltammetric and UV-vis spectrophotometric measurements and the obtained data were used for reconciled characterization of iron (III)-citrate complexes. Four different redox processes


Gold Nanorod Synthesis

Plasmonic nanoparticles have unique optical properties that can be tailored to suit a variety of applications in the biotechnology1–8 and electronics9–16 industries.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service